Affiliation:
1. Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, The James Comprehensive Cancer Center, Columbus, OH 43210, USA
Abstract
Transplant oncology is a relatively new field in which transplantation is used to treat patients who would otherwise be unresectable. New anticancer treatment paradigms using tumor and transplant immunology and cancer immunogenomics are emerging. In turn, liver transplantation (LT) has become a potential therapy for certain patients with colorectal cancer (CRC) with liver metastasis, hepatocellular (HCC), cholangiocarcinoma (CCA), and metastatic neuroendocrine tumor (NET) of the liver. Although there are established criteria for LT in HCC, evidence regarding LT as a treatment modality for certain gastrointestinal malignancies is still debated. The aim of this review is to highlight updates in the role of LT for certain malignancies, including HCC, metastatic CRC, hilar CCA, and neuroendocrine tumor (NET), as well as contextualize LT use and discuss controversies in transplant oncology.
Reference134 articles.
1. Epidemiology of Hepatocellular Carcinoma;McGlynn;Hepatology,2021
2. Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival;Jemal;J. Natl. Cancer Inst.,2017
3. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015;Akinyemiju;JAMA Oncol.,2017
4. Pathogenesis, diagnosis, and management of cholangiocarcinoma;Rizvi;Gastroenterology,2013
5. Biliary tract cancer treatment: Results from the Biliary Tract Cancer Statistics Registry in Japan;Nagakawa;J. Hepatobiliary Pancreat Surg.,2002
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献